Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. (Nasdaq: REPL) generates frequent news as a clinical stage biotechnology company developing novel oncolytic immunotherapies based on its proprietary HSV‑1‑derived RPx platform. Headquartered in Woburn, Massachusetts and founded in 2015, the company focuses on product candidates such as RP1 (vusolimogene oderparepvec) and RP2, which are being studied across multiple difficult‑to‑treat cancers.
News related to Replimune commonly covers clinical trial updates from programs like IGNYTE, IGNYTE‑3, ARTACUS and REVEAL. These updates include data presentations at major medical meetings, such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress, where the company has reported biomarker findings, response rates, durability of responses and safety data for RP1 plus nivolumab in advanced melanoma and non‑melanoma skin cancers.
Another major category of news involves regulatory milestones. Replimune has announced the FDA’s Complete Response Letter for the Biologics License Application (BLA) for RP1 in combination with nivolumab in advanced melanoma, subsequent Type A meetings with the FDA, and the agency’s acceptance of a BLA resubmission with a specified PDUFA target action date. These items are closely followed by investors and the oncology community because they reflect the evolving regulatory path for RP1.
Replimune’s news flow also includes corporate and financial updates, such as quarterly financial results, cash runway commentary, and equity‑based inducement grants to employees, as well as participation in investor conferences like the J.P. Morgan Healthcare Conference. Together, these announcements provide insight into the company’s operational progress, clinical development priorities and interactions with regulators.
Investors, clinicians and other stakeholders can use this news feed to track key developments around Replimune’s RPx platform, its lead programs in advanced melanoma and skin cancers, and the broader pipeline in metastatic uveal melanoma, hepatocellular carcinoma and biliary tract cancer.
Replimune Group, Inc. (NASDAQ: REPL) reported fiscal year 2021 financial results, ending with approximately $476 million in cash, projected to fund operations into the second half of 2024. The company announced the addition of a complete response endpoint in the CERPASS clinical trial for non-melanoma skin cancer, aiming to enhance regulatory approval prospects. Additionally, they dosed the first patient in a new NSCLC cohort and strengthened the management team with key hires for commercial preparation.
Replimune Group, Inc. (Nasdaq: REPL) has appointed Tanya Lewis as Chief Development Operations Officer, effective May 10, 2021. Previously a board member, Lewis brings extensive experience from her roles at Karyopharm Therapeutics and other biopharmaceutical firms. She will focus on executing clinical and regulatory strategies for BLA filings and product registrations. CEO Philip Astley-Sparke highlighted her potential to enhance the company’s ambition to broaden its immuno-oncology treatments. Replimune is committed to advancing its oncolytic immuno-gene therapies to address various cancer types.
Replimune Group, Inc. (Nasdaq: REPL) announced updates on its CERPASS and IGNYTE clinical trials. The Phase 2 CERPASS trial of RP1 with Libtayo for cutaneous squamous cell carcinoma will now include complete response (CR) rate as a primary endpoint, reducing target enrollment from 240 to 180 patients. Initial data is expected in 2022. Additionally, Replimune had a Type B meeting with the FDA regarding the IGNYTE trial for anti-PD1 failed melanoma, indicating a potential path for accelerated approval if data is compelling.
Replimune Group Inc. (NASDAQ: REPL) will host an investor event on June 3, 2021, at 8:00 AM ET, to discuss data from its Phase 2 skin cancer studies involving RP1 combined with Opdivo and Phase 1 results of RP2. Presentations will be made by leading experts, including CEO Philip Astley-Sparke and Robert Coffin, Ph.D., President of R&D. Attendees can access the live webcast on the company's website, with a replay available afterwards. Replimune focuses on developing innovative oncolytic immuno-gene therapies through its Immulytic® platform.
Replimune Group, Inc. (Nasdaq: REPL) announced the appointment of Sushil Patel, Ph.D. as Chief Commercial Officer, effective May 3, 2021. Patel, formerly with Genentech, brings over 20 years of oncology experience and will lead Replimune's commercial team. Notably, he was responsible for significant successful drug launches, generating over $3.5 billion in annual sales. The company plans to grant him stock options and restricted stock units upon his employment start date. This strategic leadership move aims to bolster the development and commercialization of Replimune’s oncolytic immuno-gene therapies.
Replimune Group announced promising data on its oncolytic immuno-gene therapies RP1 and RP2 at the AACR 2021 Annual Meeting. Key findings include increased infiltration of CD8+ T cells and PD-L1 expression in patients treated with RP1 and RP2, suggesting robust systemic immune activation. Pre-clinical studies also indicated potent anti-tumor activity driven by GALV-GP R- expression. The data support RP1 and RP2's potential as effective treatment options, particularly in hard-to-treat cancers, enhancing tumor destruction while minimizing off-target effects.
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company focused on oncolytic immuno-gene therapies, will present two posters at the AACR Annual Meeting 2021, held virtually from April 10-15 and May 17-21, 2021. The presentations include:
- LB180: Clinical biomarker studies on oncolytic HSV (RP1 and RP2) combined with nivolumab, scheduled for April 10 at 8:30 am EDT.
- 1917: Immunomodulatory effects of a novel herpes simplex virus platform with anti PD-1 therapy, also on April 10 at 8:30 am EDT.
Both posters will be available on-demand from April 10.
Replimune Group, Inc. (Nasdaq: REPL) announced participation in three upcoming virtual investor conferences. The H.C. Wainwright Global Life Sciences Conference will be held on March 9-10, 2021, featuring a live presentation on March 9 at 7:00 am ET. The Barclays Global Healthcare Conference takes place on March 11, 2021, with a fireside chat scheduled for 9:10 am ET. Lastly, the 33rd Annual Roth Conference is set for March 17, 2021, at 1:30 pm ET. A webcast of the Barclays presentation will be available for replay on Replimune's website for 90 days.
Replimune Group, Inc. (NASDAQ: REPL) announced that CEO Philip Astley-Sparke will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:40 AM ET. The presentation will be available via webcast on Replimune's website, with a replay accessible for 90 days post-conference.
Founded in 2015 and based in Woburn, Massachusetts, Replimune is developing oncolytic immuno-gene therapies using its proprietary Immulytic™ platform, aiming to enhance immune responses to cancer treatments.
Replimune Group (NASDAQ: REPL) reported its fiscal third quarter results for 2020, revealing a net loss of $21.8 million, up from $16.2 million a year prior. The company highlighted its progress in advancing its clinical candidates, particularly RP1, RP2, and RP3, with several studies ongoing and initial data expected throughout 2021. Additionally, Replimune's cash position stands at $493.3 million, extending its runway through the second half of 2024. However, the company noted that COVID-19 has impeded patient enrollment in clinical trials.